Some examples of target genetic mutations include EGFR in lung cancer, which responds to gefitinib and erlotinib therapy, and the Bcr-Abl fusion gene in chronic myelogenous leukemia, which is effectively treated with imatinib [6,7,8]. Here, EGFR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.